Author:
Sibona Mattia,Marra Giancarlo,Gontero Paolo
Publisher
Springer International Publishing
Reference35 articles.
1. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.
2. Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet J, Henry AM, Lam TB, Mason MD, van der Kwast TH, van der Poel HG, Rouvière O, Tilki D, Wiegel T; Members of the EAU - ESTRO - ESUR - SIOG Prostate Cancer Guidelines Panel. EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer. Edn. Presented at the EAU Annual Congress Barcelona; 2019. ISBN 978-94-92671-05-9. EAU Guidelines Office. Arnhem, The Netherlands.
3. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112:307–14.
4. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598–604.
5. Mbeutcha A, Chauveinc L, Bondiau PY, Chand ME, Durand M, Chevallier D, Amiel J, Kee DLC, Hannoun-Lévi JM. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol. 2017;12(1):49.